WallStSmart

Cosmos Health Inc. (COSM)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 100660% more annual revenue ($65.77B vs $65.27M). MRK leads profitability with a 13.6% profit margin vs -29.3%. MRK earns a higher WallStSmart Score of 50/100 (D+).

COSM

Hold

38

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 4.0
Piotroski: 4/9Altman Z: -2.25

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 3.3Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for COSM.

MRKOvervalued (-13.8%)

Margin of Safety

-13.8%

Fair Value

$97.84

Current Price

$111.28

$13.44 premium

UndervaluedFair: $97.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COSM2 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
38.5%10/10

Revenue surging 38.5% year-over-year

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$277.36B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

COSM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$17.39M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-89.1%2/10

ROE of -89.1% — below average capital efficiency

Free Cash FlowQuality
$-4.70M2/10

Negative free cash flow — burning cash

MRK4 concerns · Avg: 3.3/10
P/E RatioValuation
31.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
5.282/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : COSM

The strongest argument for COSM centers on Price/Book, Revenue Growth. Revenue growth of 38.5% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : COSM

The primary concerns for COSM are EPS Growth, Market Cap, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

COSM profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.

COSM carries more volatility with a beta of 4.30 — expect wider price swings.

COSM is growing revenue faster at 38.5% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 38/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cosmos Health Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cosmos Holdings Inc. is a vertically integrated pharmaceutical company. The company is headquartered in Chicago, Illinois.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?